Viromed Medical’s MDR Milestone Triggers 43% Rebound After Brutal Selloff

Viromed shares rebound 43% after EU regulatory approval for ViroCAP med, offsetting a 37% plunge from weak 2025 revenue and scrapped 2026 targets.

The same week that sent Viromed Medical shares crashing to a 52-week low has ended with a dramatic reversal. After the medtech group’s preliminary 2025 figures and a slashed 2026 outlook drove the stock down 37% to €4.52 on Friday, news of a long-awaited regulatory certification sparked a 43% surge on Tradegate, lifting the price to €6.50.

The catalyst was the completion of the EU Medical Device Regulation (MDR) conformity assessment for Viromed’s flagship product, ViroCAP med. The device, which uses cold?plasma technology to inactivate viruses, bacteria and multi?resistant pathogens, has now secured Class IIa classification. That clears the way for full European marketing. The company officially launched the product at the European Wound Management Association (EWMA) congress in Bremen from 6–8 May, where CEO Uwe Perbandt reported strong international interest, including multiple requests for exclusive distribution agreements.

But the regulatory win arrives against a backdrop of missed targets and strategic recalibration. Viromed had originally guided for 2025 revenue of €8–10 million, but the MDR delay – which pushed certification back by roughly seven months – meant actual revenue came in at just €5.1 million. One large order worth €2.4 million could not be delivered in time and has been shifted to 2026, where it is expected to hit the income statement.

On the bottom line, however, the picture brightened considerably. Viromed swung to a preliminary net profit of €0.6 million for 2025, compared with a loss of €3.1 million a year earlier. That turnaround underscores the underlying improvement in the business – even if the top?line disappointment overshadowed it for investors.

The more jarring change was the removal of the 2026 revenue target. Management had previously forecast sales of around €80 million and a “clearly double?digit” EBIT margin for that year. That guidance was scrapped after delays in both ViroCAP’s market rollout and the planned launch of PulmoPlas®. Instead, the board now anticipates merely a “significant increase” over 2025 – with no hard figure attached. The vagueness triggered the initial sell?off last Friday.

Analysts at mwb research stuck by their buy rating and €10.00 price target, arguing that the MDR certification is the key step needed to convert the company’s technology into scalable revenue. The international interest seen at the EWMA congress, they said, supports that thesis. With the stock still trading more than 35% below that target, the upside narrative remains alive – but only if the demand pipeline hardens into booked orders.

Investors now face a waiting game. The next hard data point arrives on 22 May, when Viromed publishes its audited 2025 financial statements. By then, the market will be watching for confirmation of the preliminary profit figure and, more importantly, any colour on how the delayed €2.4 million order and new MDR?driven contracts are developing. Given an annualised volatility above 132%, the share is not for the faint?hearted – but the whiplash of the past week shows just how quickly sentiment can turn when regulatory milestones finally arrive.